231 related articles for article (PubMed ID: 12643475)
1. Therapeutic targets for metastatic prostate cancer.
Timme TL; Satoh T; Tahir SA; Wang H; Teh BS; Butler EB; Miles BJ; Amato RJ; Kadmon D; Thompson TC
Curr Drug Targets; 2003 Apr; 4(3):251-61. PubMed ID: 12643475
[TBL] [Abstract][Full Text] [Related]
2. Castrate-resistant prostate cancer: therapeutic strategies.
Harzstark AL; Small EJ
Expert Opin Pharmacother; 2010 Apr; 11(6):937-45. PubMed ID: 20307219
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapy for advanced prostate cancer: Looking through new lenses.
Vogiatzi P; Cassone M; Claudio L; Claudio PP
Drug News Perspect; 2009 Dec; 22(10):593-601. PubMed ID: 20140279
[TBL] [Abstract][Full Text] [Related]
4. CD147/EMMPRIN and CD44 are potential therapeutic targets for metastatic prostate cancer.
Hao JL; Cozzi PJ; Khatri A; Power CA; Li Y
Curr Cancer Drug Targets; 2010 May; 10(3):287-306. PubMed ID: 20370680
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer vaccines: current status and future potential.
Doehn C; Böhmer T; Kausch I; Sommerauer M; Jocham D
BioDrugs; 2008; 22(2):71-84. PubMed ID: 18345705
[TBL] [Abstract][Full Text] [Related]
6. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers.
Zhang S; Zhang HS; Reuter VE; Slovin SF; Scher HI; Livingston PO
Clin Cancer Res; 1998 Feb; 4(2):295-302. PubMed ID: 9516914
[TBL] [Abstract][Full Text] [Related]
7. Development of dendritic-cell based prostate cancer vaccine.
Tjoa BA; Murphy GP
Immunol Lett; 2000 Sep; 74(1):87-93. PubMed ID: 10996633
[TBL] [Abstract][Full Text] [Related]
8. New prospectives of prostate cancer gene therapy: molecular targets and animal models.
Hsieh CL; Chung LW
Crit Rev Eukaryot Gene Expr; 2001; 11(1-3):77-120. PubMed ID: 11693967
[TBL] [Abstract][Full Text] [Related]
9. Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffey-Holden Prostate Cancer Academy Meeting.
Miyahira AK; Roychowdhury S; Goswami S; Ippolito JE; Priceman SJ; Pritchard CC; Sfanos KS; Subudhi SK; Simons JW; Pienta KJ; Soule HR
Prostate; 2017 Feb; 77(2):123-144. PubMed ID: 27679977
[TBL] [Abstract][Full Text] [Related]
10. In situ gene therapy for prostate cancer: immunomodulatory approaches.
Thompson TC; Timme TL; Ebara S; Satoh T; Yang G; Wang J; Miles BJ; Ayala G; Wheeler TM; Kadmon D
Expert Opin Biol Ther; 2001 May; 1(3):481-95. PubMed ID: 11727520
[TBL] [Abstract][Full Text] [Related]
11. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
Hwang C; Sanda MG
Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
[TBL] [Abstract][Full Text] [Related]
12. In situ gene therapy for prostate cancer.
Satoh T; Irie A; Egawa S; Baba S
Curr Gene Ther; 2005 Feb; 5(1):111-9. PubMed ID: 15638715
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapeutics in development for prostate cancer.
Harzstark AL; Small EJ
Oncologist; 2009 Apr; 14(4):391-8. PubMed ID: 19342474
[TBL] [Abstract][Full Text] [Related]
14. Advances in specific immunotherapy for prostate cancer.
Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for metastatic prostate cancer: immuno-cold or the tip of the iceberg?
Laccetti AL; Subudhi SK
Curr Opin Urol; 2017 Nov; 27(6):566-571. PubMed ID: 28825923
[TBL] [Abstract][Full Text] [Related]
16. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
van den Eertwegh AJ; Versluis J; van den Berg HP; Santegoets SJ; van Moorselaar RJ; van der Sluis TM; Gall HE; Harding TC; Jooss K; Lowy I; Pinedo HM; Scheper RJ; Stam AG; von Blomberg BM; de Gruijl TD; Hege K; Sacks N; Gerritsen WR
Lancet Oncol; 2012 May; 13(5):509-17. PubMed ID: 22326922
[TBL] [Abstract][Full Text] [Related]
17. What's new in the treatment of advanced prostate cancer?
Sternberg CN
Eur J Cancer; 2003 Jan; 39(2):136-46. PubMed ID: 12509944
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy: a glimmer of hope for metastatic prostate cancer.
Jindal V
Chin Clin Oncol; 2018 Dec; 7(6):61. PubMed ID: 29860848
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for prostate cancer - recent progress in clinical trials.
Kipp RT; McNeel DG
Clin Adv Hematol Oncol; 2007 Jun; 5(6):465-74, 477-9. PubMed ID: 17679921
[TBL] [Abstract][Full Text] [Related]
20. Development of PROSTVAC immunotherapy in prostate cancer.
Singh P; Pal SK; Alex A; Agarwal N
Future Oncol; 2015; 11(15):2137-48. PubMed ID: 26235179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
